Gadolinium Deposition Disease Lawsuit – Gadolinium Toxicity

Written By:
Jessie Paluch
Jessie Paluch

Attorney Jessie Paluch, founder of TruLaw, has over 25 years of experience as a personal injury and mass tort attorney, and previously worked as an international tax attorney at Deloitte. Jessie collaborates with attorneys nationwide — enabling her to share reliable, up-to-date legal information with our readers.

This article has been written and reviewed for legal accuracy and clarity by the team of writers and legal experts at TruLaw and is as accurate as possible. This content should not be taken as legal advice from an attorney. If you would like to learn more about our owner and experienced injury lawyer, Jessie Paluch, you can do so here.

TruLaw does everything possible to make sure the information in this article is up to date and accurate. If you need specific legal advice about your case, contact us by using the chat on the bottom of this page. This article should not be taken as advice from an attorney.

Was I Exposed To Gadolinium In A Recent MRI?

According to the Organization for Economic Cooperation and Development, 38 million MRI imaging exams are performed in the U.S. each year.

30% of those exams utilize a Gadolinium-based contrast agent (GBCA) – exposing 11.4 million U.S. citizens per year to Gadolinium.

Gadolinium-based contrast agents are used with medical imaging devices called MRI (Magnetic Resonance Imaging) scanners to examine the body for problems such as cancer infections or bleeding.

Gadolinium Deposition Disease Lawsuit Gadolinium Toxicity

These Gadolinium-based contrast agents are injected into a vein to improve visualization of internal organs and it helps to diagnose medical conditions.

The market for contrast agents is expected to reach $5.53 billion by 2022.

It is imperative that U.S. GBCA risk studies continue to move forward in the U.S.

When used on individuals with normal kidney function, GBCAs have been assumed to be eliminated from the body through the kidneys.

But, recent studies may contradict that assumption.

Table of Contents

Studies Lead To Warnings And More Questions

Since September 2010, the FDA has required that gadolinium-based contrast agents (GBCA) carry a warning on their label about the risk of Nephrogenic Systemic Fibrosis (NSF) when administered in individuals with kidney disease.

NSF is a disease of fibrosis of the skin and organs.

Fibrosis is characterized by a thickening or hardening of the skin and most often appears in the arms and legs.

NSF diagnosis have decreased substantially since MRI/MRA protocol have required kidney testing prior to using gadolinium as a contrast agent.

In 2014, Japanese scientists reported gadolinium was found in the brains of deceased patients who never had kidney disease.

This study led to the finding that a small quantity of gadolinium will remain in the patient for an indeterminate amount of time, regardless of renal function.

Gadolinium Deposition Disease (GDD)

As a result of these studies, a new disease referred to as gadolinium deposition disease (GDD) was identified.

GDD appears to have similar, but less severe, symptoms than NSF, including:

  • Persistent headache
  • Bone pain
  • Joint pain
  • Subcutaneous soft tissue thickening (skin that appears spongy or rubbery)
  • Tendons and ligaments are painful and have thickened
  • Tightness in hands and feet
  • Pain described as burning, cutting, or pins and needles in the arms, legs or torso.

GDD symptoms appear anywhere from a few hours to a few weeks after injection with a GBCA and generally requires diagnosis through a urine test.

In June 2015, the Mayo Clinic found direct evidence of gadolinium deposition in brain tissue during the autopsies of individuals who had MRIs prior to donating their bodies to medical research upon death.

Further research has led scientists to consider whether there are safer GBCAs.

This was the approach taken by the European Medicines Agency (EMA) during a study of gadolinium deposition in the brain and other tissues.

In July 2015, this study led to the suspension of linear gadolinium agents including Magnevist, Multihance, Omniscan, and Optimark.

The FDA is still studying the effects of gadolinium and has not yet suspended the use of any of the GBCAs.

However, on December 19, 2017, The FDA issued a safety alert to the public and now requires a warning to be shared with all patients about the risk of gadolinium retention.

Gadolinium Lawsuits

After five years of intense burning, heart pounding and other side effects from an MRI scan, Gena Norris, wife of actor and martial artist, Chuck Norris, filed a lawsuit in San Francisco Superior court alleging the GBCA used in her MRI poisoned her.

In addition, many other cases have been filed in other states, and it is expected that hundreds of these gadolinium lawsuits will be filed soon.

Gadolinium Settlement

In 2008, scores of plaintiffs successfully argued that manufacturers of GCBAs failed to warn about the risk of nephrogenic systemic fibrosis in patients with renal failure or kidney impairment.

These lawsuits resulted in settlements and an FDA warning.

Lawsuits filed on behalf of individuals experiencing GDD are still making their way through court.

There are currently no reported settlements of these cases.

It is quite likely that settlement discussions will occur at some point.

Written By:
Jessie Paluch
Jessie Paluch

Experienced Attorney & Legal SaaS CEO

With over 25 years of legal experience, Jessie is an Illinois lawyer, a CPA, and a mother of three.  She spent the first decade of her career working as an international tax attorney at Deloitte.

In 2009, Jessie co-founded her own law firm with her husband – which has scaled to over 30 employees since its conception.

In 2016, Jessie founded TruLaw, which allows her to collaborate with attorneys and legal experts across the United States on a daily basis. This hypervaluable network of experts is what enables her to share reliable legal information with her readers!

Camp Lejeune Lawsuit

Camp Lejeune’s water contamination issue spanned several decades starting in the 1950s. Exposure to these chemicals has been linked to various serious health issues, including cancer, organ diseases, and death.

Tylenol Lawsuit

Research is increasingly suggesting a link between the use of Tylenol during pregnancy and the development of neurodevelopmental disorders, such as autism and ADHD, in infants.

AFFF Lawsuit

Legal action is being taken against manufacturers of Aqueous Film-Forming Foam (AFFF), a chemical used in fighting fires. The plaintiffs allege that exposure to the foam caused health issues such as cancer, organ damage, and birth and fertility issues.

Do You
Have A Case?

Here, at TruLaw, we’re committed to helping victims get the justice they deserve.

Alongside our partner law firms, we have successfully collected over $3 Billion in verdicts and settlements on behalf of injured individuals.

Would you like our help?

Helpful Sites & Resources